Navigation Links
ShangPharma Announces Second Quarter 2011 Results
Date:8/22/2011

ures also facilitate management's internal comparisons to the Company's historical performance. The Company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The Company believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. A limitation of using non-GAAP financial measures excluding expenses relating to or the effect of share-based compensation is that these expenses and effects have been and will continue to be significant recurring expenses in the Company's business for the foreseeable future. Management compensates for these limitations by providing specific information regarding the GAAP amount excluded from each non-GAAP measure. The accompanying tables have more details on the reconciliation between non-GAAP financial measures and their most comparable GAAP financial measures.

For further information, please contact:ShangPharma CorporationIn Shanghai, China
Lan Xie
VP of Finance and Operations
E-mail: IR@shangpharma.comChristensen

In New York, US
Kimberly Minarovich, +1 917-533-3268
kminarovich@christensenir.comIn Hong Kong
Tip Fleming, +852-9212-0684
tfleming@christensenir.comSHANGPHARMA CORPORATIONUNAUDITED CONSOLIDATED BALANCE SHEET(in thousands of U.S. dollars, except for ordinary share data) 

 

December 31,

June 30,  

 

2010

2011 ASSETSCurrent assets: 

 Cash and cash equivalents

49,160

41,550 

 Restricted cash

688

840 

 Accounts receivable, net

16,908

20,261 

 A
'/>"/>

SOURCE ShangPharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. ShangPharma Corporation Named a Top Ten Chinese Outsourcing Enterprise
2. ShangPharma Announces First Quarter 2011 Results
3. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
4. Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc.
5. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
6. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
7. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
8. Neurologix Announces Second Quarter 2011 Financial Results
9. Bion Announces New U.S. Patent for Phosphorus Removal
10. ViaCyte Announces Executive Management Changes
11. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Gene synthesis and bioengineering company ... into a technology access and services agreement with ... proprietary protein engineering technology, known as “ProteinGPS®” to ... extremely excited that the global leader ADM has ... bioengineering technology has now been validated through many ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/15/2014)... Israel , Dec. 15, 2014 /PRNewswire/ ... a leading developer of adult stem cell technologies for ... Therapeutics Ltd. was awarded a grant of approximately $1.1 ... the Chief Scientist (OCS).  This is the eighth year ... from the Office of the Chief Scientist, which is ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... the Annual Report to the Nation on the Status ... deaths for many types of cancers. This encouraging news can ... smoking and improved diet, and early detection. ... the blood cancers, early detection is rare, there are no ...
... Neb., April 1, 2011 Transgenomic, Inc. ... have completed studies employing the company,s high-sensitivity cancer ... and BLOCker™-Sequencing.  Results from these studies will be ... (AACR) meeting in Orlando, Florida, April 2-6, 2011. ...
... NY As part of the quest to form ... electronic, and medical devices, researchers at the U.S. Department ... molecules in thin films remain frozen at a temperature ... have a range of applications extending from organic solar ...
Cached Biology Technology:The Leukemia & Lymphoma Society: Accelerating Cures Must Be a Priority 2Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 2Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 3Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting 4Expanding the degrees of surface freezing 2
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
(Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... been found to negatively affect these teenagers health in ... and cancers of the reproductive system. Given these findings, ... at increased risk for early puberty in order to ... youths., New research shows that greater support from mothers ...
... -- In response to the need for localized efforts ... threatened staghorn coral, Diego Lirman, Ph.D., and James Herlan, ... Marine and Atmospheric Science (RSMAS) have established an ... The goals of the coral nursery are to ...
... Inc.,(Pink Sheets: ESMT) ("e-Smart" or the "Company") responds ... in which a series of serious allegations,are made ... as untrue, inaccurate and misleading. IDsmart is operated ... plead guilty to,securities fraud charges in the U.S. ...
Cached Biology News:Family conditions may affect when girls experience puberty 2New south Florida nursery to focus on staghorn corals 2e-Smart Technologies Responds to Press Release Issued By IDsmart LLC 2e-Smart Technologies Responds to Press Release Issued By IDsmart LLC 3
Ms anti-Cyclophilin D...
Protein Kinase D2 Immunogen: Human protein kinase D2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: